|
Volumn 14, Issue 6, 2001, Pages 396-404
|
Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation
a a a a a a a a |
Author keywords
Basilixmab; Daclizumab; Kidney pancreas transplantation; Outcome; Rejection
|
Indexed keywords
COTRIMOXAZOLE;
GANCICLOVIR;
INTERLEUKIN 2 RECEPTOR ANTIBODY;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
STEROID;
TACROLIMUS;
THYMOCYTE ANTIBODY;
ADULT;
ARTICLE;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG EFFICACY;
DRUG SAFETY;
FEMALE;
GRAFT REJECTION;
GRAFT SURVIVAL;
HUMAN;
KIDNEY FUNCTION;
KIDNEY TRANSPLANTATION;
MALE;
PANCREAS FUNCTION;
PANCREAS TRANSPLANTATION;
PRIORITY JOURNAL;
SIDE EFFECT;
SURVIVAL RATE;
ADRENAL CORTEX HORMONES;
ADULT;
ANTIBODIES, MONOCLONAL;
FEMALE;
GRAFT REJECTION;
GRAFT SURVIVAL;
HUMANS;
IMMUNOGLOBULIN G;
IMMUNOSUPPRESSIVE AGENTS;
KIDNEY TRANSPLANTATION;
MALE;
MIDDLE AGED;
MYCOPHENOLIC ACID;
PANCREAS TRANSPLANTATION;
PROSPECTIVE STUDIES;
RECEPTORS, INTERLEUKIN-2;
RECOMBINANT FUSION PROTEINS;
TACROLIMUS;
|
EID: 0035664439
PISSN: 09340874
EISSN: None
Source Type: Journal
DOI: 10.1007/s001470100005 Document Type: Article |
Times cited : (19)
|
References (26)
|